By Fineline Cube 
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its in-house developed mRNA-based shingles vaccine in China and the United States. The company has received regulatory approvals in both countries to proceed with the trials.
Innovative Vaccine Performance
In preclinical studies, AIM Vaccine’s product demonstrated significantly stronger performance than current mainstream recombinant subunit vaccines. It showed superior results in inducing specific T-cell responses and antibody titers.
Market Potential
Global sales of GSK’s mRNA shingles vaccine reached USD 4.3 billion in 2024, while the Chinese market for mRNA shingles vaccines is projected to reach RMB 20 billion (USD 2.8 billion) by 2030. This indicates substantial market potential for AIM Vaccine’s innovative product.-Fineline Info & Tech